VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice

Ming Sun, Yue Li, Zhe Yuan, Wuxun Lu, Guobin Kang, Wenjin Fan, Qingsheng Li

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Broadly neutralizing antibodies (bNAbs) represent a new generation of antiviral agents for the prevention and treatment of human immunodeficiency virus 1 (HIV-1) infection. A better understanding of the in vivo efficacy of HIV-1 bNAbs, such as VRC01, in preventing mucosal transmission of HIV-1 has important implications for HIV-1 vaccine design. In this study, we evaluated the efficacy of passively transferred VRC01 antibody in preventing HIV-1 vaginal and rectal transmission in humanized bone marrow/liver/thymus mice (hu-BLT mice). Mice were subcutaneously injected with VRC01 IgG, and 24 hours later, they were challenged intravaginally or intrarectally with HIV-1Ada. All hu-BLT mice receiving VRC01 IgG antibody were aviremic at 2 weeks after intravaginal (n = 3) or intrarectal (n = 6) challenge as measured by quantitative real-time RT-PCR. In contrast, mice receiving control IgG all became infected. By 5 and 6 weeks post-challenge, some of VRC01 aviremic mice in both the intravaginal and intrarectal challenge groups became viremic. Our results suggest that VRC01 antibody can be protective against HIV-1 vaginal and rectal transmission; however, a single administration of VRC01 cannot completely prevent mucosal infection.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalArchives of Virology
DOIs
StateAccepted/In press - Jun 24 2016

Fingerprint

Thymus Gland
HIV-1
Bone Marrow
Antibodies
Liver
Immunoglobulin G
Neutralizing Antibodies
Virus Diseases
Antiviral Agents
Real-Time Polymerase Chain Reaction
Vaccines
HIV
Infection

ASJC Scopus subject areas

  • Virology

Cite this

VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice. / Sun, Ming; Li, Yue; Yuan, Zhe; Lu, Wuxun; Kang, Guobin; Fan, Wenjin; Li, Qingsheng.

In: Archives of Virology, 24.06.2016, p. 1-7.

Research output: Contribution to journalArticle

Sun, Ming ; Li, Yue ; Yuan, Zhe ; Lu, Wuxun ; Kang, Guobin ; Fan, Wenjin ; Li, Qingsheng. / VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice. In: Archives of Virology. 2016 ; pp. 1-7.
@article{ddacf76c94f14ee280f643a42ff3a8c5,
title = "VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice",
abstract = "Broadly neutralizing antibodies (bNAbs) represent a new generation of antiviral agents for the prevention and treatment of human immunodeficiency virus 1 (HIV-1) infection. A better understanding of the in vivo efficacy of HIV-1 bNAbs, such as VRC01, in preventing mucosal transmission of HIV-1 has important implications for HIV-1 vaccine design. In this study, we evaluated the efficacy of passively transferred VRC01 antibody in preventing HIV-1 vaginal and rectal transmission in humanized bone marrow/liver/thymus mice (hu-BLT mice). Mice were subcutaneously injected with VRC01 IgG, and 24 hours later, they were challenged intravaginally or intrarectally with HIV-1Ada. All hu-BLT mice receiving VRC01 IgG antibody were aviremic at 2 weeks after intravaginal (n = 3) or intrarectal (n = 6) challenge as measured by quantitative real-time RT-PCR. In contrast, mice receiving control IgG all became infected. By 5 and 6 weeks post-challenge, some of VRC01 aviremic mice in both the intravaginal and intrarectal challenge groups became viremic. Our results suggest that VRC01 antibody can be protective against HIV-1 vaginal and rectal transmission; however, a single administration of VRC01 cannot completely prevent mucosal infection.",
author = "Ming Sun and Yue Li and Zhe Yuan and Wuxun Lu and Guobin Kang and Wenjin Fan and Qingsheng Li",
year = "2016",
month = "6",
day = "24",
doi = "10.1007/s00705-016-2942-4",
language = "English (US)",
pages = "1--7",
journal = "Archives of Virology",
issn = "0304-8608",
publisher = "Springer Wien",

}

TY - JOUR

T1 - VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice

AU - Sun, Ming

AU - Li, Yue

AU - Yuan, Zhe

AU - Lu, Wuxun

AU - Kang, Guobin

AU - Fan, Wenjin

AU - Li, Qingsheng

PY - 2016/6/24

Y1 - 2016/6/24

N2 - Broadly neutralizing antibodies (bNAbs) represent a new generation of antiviral agents for the prevention and treatment of human immunodeficiency virus 1 (HIV-1) infection. A better understanding of the in vivo efficacy of HIV-1 bNAbs, such as VRC01, in preventing mucosal transmission of HIV-1 has important implications for HIV-1 vaccine design. In this study, we evaluated the efficacy of passively transferred VRC01 antibody in preventing HIV-1 vaginal and rectal transmission in humanized bone marrow/liver/thymus mice (hu-BLT mice). Mice were subcutaneously injected with VRC01 IgG, and 24 hours later, they were challenged intravaginally or intrarectally with HIV-1Ada. All hu-BLT mice receiving VRC01 IgG antibody were aviremic at 2 weeks after intravaginal (n = 3) or intrarectal (n = 6) challenge as measured by quantitative real-time RT-PCR. In contrast, mice receiving control IgG all became infected. By 5 and 6 weeks post-challenge, some of VRC01 aviremic mice in both the intravaginal and intrarectal challenge groups became viremic. Our results suggest that VRC01 antibody can be protective against HIV-1 vaginal and rectal transmission; however, a single administration of VRC01 cannot completely prevent mucosal infection.

AB - Broadly neutralizing antibodies (bNAbs) represent a new generation of antiviral agents for the prevention and treatment of human immunodeficiency virus 1 (HIV-1) infection. A better understanding of the in vivo efficacy of HIV-1 bNAbs, such as VRC01, in preventing mucosal transmission of HIV-1 has important implications for HIV-1 vaccine design. In this study, we evaluated the efficacy of passively transferred VRC01 antibody in preventing HIV-1 vaginal and rectal transmission in humanized bone marrow/liver/thymus mice (hu-BLT mice). Mice were subcutaneously injected with VRC01 IgG, and 24 hours later, they were challenged intravaginally or intrarectally with HIV-1Ada. All hu-BLT mice receiving VRC01 IgG antibody were aviremic at 2 weeks after intravaginal (n = 3) or intrarectal (n = 6) challenge as measured by quantitative real-time RT-PCR. In contrast, mice receiving control IgG all became infected. By 5 and 6 weeks post-challenge, some of VRC01 aviremic mice in both the intravaginal and intrarectal challenge groups became viremic. Our results suggest that VRC01 antibody can be protective against HIV-1 vaginal and rectal transmission; however, a single administration of VRC01 cannot completely prevent mucosal infection.

UR - http://www.scopus.com/inward/record.url?scp=84976259402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976259402&partnerID=8YFLogxK

U2 - 10.1007/s00705-016-2942-4

DO - 10.1007/s00705-016-2942-4

M3 - Article

SP - 1

EP - 7

JO - Archives of Virology

JF - Archives of Virology

SN - 0304-8608

ER -